A J M Beijers1,2, G Vreugdenhil3,4, S Oerlemans5,6, M Eurelings7, M C Minnema8, C M Eeltink9, L V van de Poll-Franse5,6, F Mols5,6. 1. Department of Internal Medicine, Máxima Medical Center, De Run 4600, Veldhoven, PO Box 7777, 5504 DB, the Netherlands. t.beijers@mmc.nl. 2. Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. t.beijers@mmc.nl. 3. Department of Internal Medicine, Máxima Medical Center, De Run 4600, Veldhoven, PO Box 7777, 5504 DB, the Netherlands. 4. Department of Medical Oncology, Maastricht University Medical Center, Maastricht, the Netherlands. 5. Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands. 6. CoRPS-Centre of Research on Psychology in Somatic diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, the Netherlands. 7. Department of Neurology, Spaarne Hospital, Hoofddorp, the Netherlands. 8. Department of Hematology, UMC Utrecht Cancer Center, Utrecht, the Netherlands. 9. Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands.
Abstract
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients' health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MM patients. METHODS: One hundred fifty-six MM patients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response). RESULTS: The psychometric analyses showed a Cronbach's alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales. CONCLUSIONS: CIPN is a common side effect in MM patients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) may negatively influence multiple myeloma (MM) patients' health-related quality of life (HRQOL). Dose modification is the only way to minimize CIPN. To measure CIPN in daily practice, the Indication for Common Toxicity Criteria (CTC) Grading of Peripheral Neuropathy Questionnaire (ICPNQ) was developed which can be completed within five minutes by the patient. The aims of this study were to (1) perform a psychometric evaluation of the ICPNQ and (2) examine the prevalence of CIPN and its influence on HRQOL in population-based MMpatients. METHODS: One hundred fifty-six MMpatients, diagnosed between 2000 and 2014, completed the ICPNQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20), and EORTC QLQ-C30 (65 % response). RESULTS: The psychometric analyses showed a Cronbach's alpha of 0.84, 0.74, and 0.61 for, respectively, the sensory, motoric, and autonomic subscales of the ICPNQ. Test-retest reliability and construct validity were good for all subscales. Overall, 65 % of patients reported grade 2-3 neuropathy according to the ICPNQ. Patients with the highest CTC grades (grade 2 with neuropathic pain and grade 3 (38 %)) according to the ICPNQ reported significantly worse scores on all EORTC QLQ-CIPN20 subscales compared to patients with lower CTC grades (p ≤ 0.002). In addition, they reported statistically significant and clinically relevant worse HRQOL scores on almost all EORTC QLQ-C30 subscales. CONCLUSIONS: CIPN is a common side effect in MMpatients, which has a negative impact on HRQOL. The ICPNQ is a valid instrument to distinguish the highest CIPN CTC grades from the lower CTC grades necessary to decide on dose modifications of chemotherapy in daily clinical practice.
Entities:
Keywords:
Chemotherapy-induced peripheral neuropathy; Health-related quality of life; Indication for CTC Grading of Peripheral Neuropathy Questionnaire; Multiple myeloma; Patient-reported questionnaire; Validation
Authors: Floortje Mols; Tonneke Beijers; Gerard Vreugdenhil; Lonneke van de Poll-Franse Journal: Support Care Cancer Date: 2014-05-01 Impact factor: 3.603
Authors: P G Richardson; M Delforge; M Beksac; P Wen; J L Jongen; O Sezer; E Terpos; N Munshi; A Palumbo; S V Rajkumar; J L Harousseau; P Moreau; H Avet-Loiseau; J H Lee; M Cavo; G Merlini; P Voorhees; W J Chng; A Mazumder; S Usmani; H Einsele; R Comenzo; R Orlowski; D Vesole; J J Lahuerta; R Niesvizky; D Siegel; M-V Mateos; M Dimopoulos; S Lonial; S Jagannath; J Bladé; J San Miguel; G Morgan; K C Anderson; B G M Durie; P Sonneveld Journal: Leukemia Date: 2011-12-23 Impact factor: 11.528
Authors: Michel Delforge; Joan Bladé; Meletios A Dimopoulos; Thierry Facon; Martin Kropff; Heinz Ludwig; Antonio Palumbo; Philip Van Damme; Jesús F San-Miguel; Pieter Sonneveld Journal: Lancet Oncol Date: 2010-11 Impact factor: 41.316
Authors: Karin Jordan; Irina Proskorovsky; Philip Lewis; Jack Ishak; Krista Payne; Noreen Lordan; Charalampia Kyriakou; Cathy D Williams; Sarah Peters; Faith E Davies Journal: Support Care Cancer Date: 2014-02 Impact factor: 3.603
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810
Authors: Simone Oerlemans; M Christine Bennink; Mark David Levin; Annemiek Broijl; Marjolein Van der Klift; Judith Van Deursen; Daphne Vogels; Lonneke V Van de Poll-Franse; Pieter Sonneveld; Jan A Hazelzet; Lidwine W Tick Journal: Hemasphere Date: 2020-05-27
Authors: Cynthia S Bonhof; Lonneke V van de Poll-Franse; Pauline A J Vissers; Dareczka K Wasowicz; Johannes A Wegdam; Dóra Révész; Gerard Vreugdenhil; Floortje Mols Journal: Psychooncology Date: 2019-07-29 Impact factor: 3.894
Authors: Sam H Ahmedzai; John A Snowden; Andrew John Ashcroft; David Allan Cairns; Cathy Williams; Anna Hockaday; Jamie D Cavenagh; Debo Ademokun; Eleni Tholouli; David Allotey; Vijay Dhanapal; Matthew Jenner; Kwee Yong; Jim Cavet; Hannah Hunter; Jennifer M Bird; Guy Pratt; Christopher Parrish; Julia M Brown; Treen C M Morris; Gordon Cook Journal: J Clin Oncol Date: 2019-04-10 Impact factor: 44.544
Authors: Maryam Omran; Elizabeth K Belcher; Nimish A Mohile; Shelli R Kesler; Michelle C Janelsins; Andrea G Hohmann; Ian R Kleckner Journal: Front Mol Biosci Date: 2021-06-11
Authors: Syeda A. Mina; Ibrahim N. Muhsen; Ethan A. Burns; Humaira Sarfraz; Sai Ravi Pingali; Jiaqiong Xu; Shahrukh K. Hashmi Journal: Turk J Haematol Date: 2021-06-30 Impact factor: 1.831